Microbiotic Analysis in Digestive Endocrine Tumors

N/AUnknownNCT04198402

Assistance Publique - Hôpitaux de Paris50 enrolled

Overview

Incidence of digestive neuroendocrine tumors are increasing. Analysis of individual microbiota is a way to explore new neoplastic mechanisms, tumor identification and therapeutic orientations. This prospective pilot study aims to describe fecal bacterial phylogeny of patients with digestive neuroendocrine tumor. Bacterial genomic signature will be recorded at initiation of Lanreotide treatment in naive patient with digestive neuroendocrine tumor (pancreas or small intestine), metastatic or locally advanced, as well as after one year follow up.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Digestive Neuroendocrine Tumor Fecal Microbiota Bacterial Signature

Interventions

Biological samplingBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years old or older * naive patient with digestive neuroendocrine tumor (pancreas (cytology or histology per endoscopy or on surgical specimen) or small intestine), secreting or not, initiating a extended release Lanreotide treatment * registered with a social security scheme Exclusion Criteria: * medical contraindication to somatostatine analogs use * history of extended release somatostatine analogs treatment * antibiotic use or colonoscopic purge in the last 3 weeks preceding fecal sample * pregnant or breastfeeding women * person requiring tutorship, guardianship, or person legally protected

Outcomes

Primary Outcomes

bacterial genomic signature

bacterial genomic signature by fecal ARN16S analysis at enrollment

Time frame: Baseline visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.